Scientists Develop Pill That Destroys Solid Cancer Tumors in Early Research


London (Parliament Politic Magazine) – Scientists have successfully developed a groundbreaking pill that, in pre-clinical research, demonstrates the potential to eradicate all solid cancer tumors while sparing healthy cells from harm. A team of researchers from City of Hope, a renowned cancer research and treatment institution in the United States, recently unveiled their remarkable findings in a study published on Tuesday.

This study delves into the initial test results of a remarkable “cancer-killing pill” known as AOH1996. The City of Hope revealed The drug focuses on a cancerous variant of proliferating cell nuclear antigen (PCNA) – a protein that plays a crucial role in DNA replication and repair for all growing tumors when it undergoes mutation.

Scientists Unveil Breakthrough Tumor Terminator Pill

Linda Malkas, a professor in the Department of Molecular Diagnostics and Experimental Therapeutics at the Californian Treatment Centre, has dedicated the last two decades to the development of a groundbreaking pill.

Throughout the course of 20 years, Professor Linda Malkas has been tirelessly working on the creation of a revolutionary pill within the esteemed Department of Molecular Diagnostics and Experimental Therapeutics at the Californian Treatment Centre.

Our revolutionary cancer-killing medication operates akin to a powerful snowstorm that effectively paralyzes a vital airline hub, causing the suspension of all incoming and outgoing flights exclusively for aircraft carrying cancer cells.

She also reveals “PCNA is like a major airline terminal hub containing multiple plane gates. “Data suggests PCNA is uniquely altered in cancer cells, and this fact allowed us to design a drug that targeted only the form of PCNA in cancer cells’’. “Our cancer-killing pill is like a snowstorm that closes a key airline hub, shutting down all flights in and out only in planes carrying cancer cells.”

The professor described the results as “promising,” emphasizing that research has demonstrated the ability of AOH1996 to inhibit tumor growth in both cell and animal models. Furthermore, the initial phase of a clinical trial involving human subjects is currently in progress.

Scientists Introduce Revolutionary Pill Targeting Solid Tumors

PCNA has never been targeted therapeutically before due to its perception as an ‘undruggable’ protein. However, City of Hope has successfully developed an investigational medicine to tackle this challenging protein target. The pill has demonstrated its efficacy in treating cells derived from various types of cancers, including prostate, brain, ovarian, cervical, skin, and lung cancers.

 Extensive testing on over 70 cancer cell lines has revealed its ability to selectively eliminate cancer cells by disrupting the regular cell reproductive cycle, as confirmed by the research center.

Remarkably, the targeted protein PCNA, previously considered “undruggable,” has now been successfully targeted by this pill. This breakthrough discovery opens up new possibilities for combating cancer and offers hope for patients worldwide.

The Lead author of the study, Long Gu, revealed: “No one has ever targeted PCNA as a therapeutic because it was viewed as ‘undruggable,’ but clearly City of Hope was able to develop an investigational medicine for a challenging protein target.”

The City of Hope has a remarkable history in groundbreaking translational research. It encompasses the development of revolutionary technologies that have transformed the field of medicine. 

Read More: UK Doctors Seek Government Support As Their Mental Health Deteriorate Amid Covid-19 Return In The UK

Researches at City of Hope Work Harder

Researchers at City of Hope, a renowned cancer research and treatment institution in the United States, have recently unveiled a groundbreaking study. This study sheds light on their remarkable achievement in harnessing the power of a protein previously deemed too formidable for targeted therapy – the proliferating cell nuclear antigen (PCNA). Through their innovative approach, they have successfully developed a targeted chemotherapy that shows immense promise in eradicating solid tumors, as demonstrated in preclinical research.

As the dedicated scientists delve deeper into unraveling the fundamental mechanisms underlying the effectiveness of this cancer-fighting treatment in animal models, it is worth noting that a Phase 1 clinical trial is currently underway. This trial aims to evaluate the therapeutic developed by City of Hope in human subjects, marking a significant milestone in the journey towards combating cancer.

Interestingly, experiments have demonstrated that the investigational pill, AOH1996, enhances the vulnerability of cancer cells to chemical agents that induce DNA or chromosome damage, including the chemotherapy drug cisplatin. This suggests that AOH1996 holds potential as a valuable asset in combination therapies, as well as in the advancement of novel chemotherapeutic treatments.

Beth Malcolm

Beth Malcolm is Scottish based Journalist at Heriot-Watt University studying French and British Sign Language. She is originally from the north west of England but is living in Edinburgh to complete her studies.